Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ivWatch Model 400: Device Validation for Infiltrated Tissues

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02123745
Recruitment Status : Completed
First Posted : April 28, 2014
Results First Posted : June 27, 2014
Last Update Posted : June 27, 2014
Sponsor:
Information provided by (Responsible Party):
ivWatch, LLC

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A single arm trial consisting of 70 adult volunteers to assess the safety and efficacy of the ivWatch Model 400 when observing infiltrated tissues at common sites for peripheral IV therapy.

Condition or disease Intervention/treatment Phase
Infiltration of Peripheral IV Therapy Device: The ivWatch Model 400 Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Study Start Date : February 2014
Actual Primary Completion Date : February 2014
Actual Study Completion Date : February 2014
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Infiltrated Tissue
The ivWatch Model 400 monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
 Device: The ivWatch Model 400
The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Red Notification Sensitivity to Infiltrated Tissues [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]
    The ratio of the number of infiltrated IV sites where the ivWatch Model 400 device issued a red notification to the total number of infiltrated IV sites in the study. All infiltrations were limited to 10 mL of isotonic saline solution.


Secondary Outcome Measures :
  1. Yellow Notification Sensitivity to Infiltrated Tissues [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]
    The ratio of the number of infiltrated IV sites where the ivWatch Model 400 device issued a yellow notification to the total number of infiltrated IV sites in the study. All infiltrations were limited to 10 mL of isotonic saline solution.

  2. Infiltrated Volume When Red Notification Issued [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]
    The amount of infiltrated isotonic saline solution when the red notification was issued by the ivWatch Model 400 device.

  3. Infiltrated Volume When Yellow Notification Issued [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]
    The amount of infiltrated isotonic saline solution when the yellow notification was issued by the ivWatch Model 400 device.

  4. Significant Skin Irritation or Disruption to Skin Integrity [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]
    The number of IV sites that indicated significant skin irritation or disruption to skin integrity assessed at the end of the study.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Informed consent
  • Pass health screen by clinician
  • 18 years or older

Exclusion Criteria:

  • Fail health screen
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02123745


Locations
Layout table for location information
United States, Virginia
ivWatch, LLC
Williamsburg, Virginia, United States, 23185
Sponsors and Collaborators
ivWatch, LLC
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: ivWatch, LLC
ClinicalTrials.gov Identifier: NCT02123745    
Other Study ID Numbers: IVW400CS-06
First Posted: April 28, 2014    Key Record Dates
Results First Posted: June 27, 2014
Last Update Posted: June 27, 2014
Last Verified: May 2014
Keywords provided by ivWatch, LLC:
infiltration
extravasation
peripheral intravenous therapy